Global Oncology Drugs Market 2021 by Company, Regions, Type and Application, Forecast to 2026

Publisher Name :
Date: 19-Oct-2021
No. of pages: 115

The Oncology Drugs market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.

According to our latest research, the global Oncology Drugs size is estimated to be USD 267640 million in 2026 from USD 183760 million in 2020, with a change XX% between 2020 and 2021. The global Oncology Drugs market size is expected to grow at a CAGR of 9.9% for the next five years.

Market segmentation

Oncology Drugs market is split by Type and by Application. For the period 2016-2026, the growth among segments provide accurate calculations and forecasts for revenue by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.

Market segment by Type, covers

- Chemotherapy

- Targeted Therapy

- Immunotherapy (Biologic Therapy)

- Hormonal Therapy

- Others

Market segment by Application, can be divided into

- Blood Cancer

- Breast Cancer

- Gastrointestinal Cancer

- Prostate Cancer

- Respiratory or Lung Cancer

- Others

Market segment by players, this report covers

- Roche

- Celgene

- Novartis

- Bristol-Myers Squibb

- Johnson & Johnson

- Merck & Co.

- AstraZeneca

- Pfizer

- Amgen

- Eli Lilly

- AbbVie

- Takeda

- Astellas

- Ipsen

- Sanofi

- Bayer

- Biogen Idec

- Teva

- Otsuka

- Eisai

- Merck KGaA

- Gilead Sciences

Market segment by regions, regional analysis covers

- North America (United States, Canada, and Mexico)

- Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)

- Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia, and Rest of Asia-Pacific)

- South America (Brazil, Argentina, Rest of South America)

- Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)

The content of the study subjects, includes a total of 12 chapters:

Chapter 1, to describe Oncology Drugs product scope, market overview, market opportunities, market driving force and market risks.

Chapter 2, to profile the top players of Oncology Drugs, with revenue, gross margin and global market share of Oncology Drugs from 2019 to 2021.

Chapter 3, the Oncology Drugs competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.

Chapter 4 and 5, to segment the market size by type and application, with revenue and growth rate by type, application, from 2016 to 2026.

Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2016 to 2021.and Oncology Drugs market forecast, by regions, type and application, with revenue, from 2021 to 2026.

Chapter 11 and 12, to describe Oncology Drugs research findings and conclusion, appendix and data source.

Global Oncology Drugs Market 2021 by Company, Regions, Type and Application, Forecast to 2026

Table of Contents

1 Market Overview
1.1 Product Overview and Scope of Oncology Drugs
1.2 Classification of Oncology Drugs by Type
1.2.1 Overview: Global Oncology Drugs Market Size by Type: 2020 Versus 2021 Versus 2026
1.2.2 Global Oncology Drugs Revenue Market Share by Type in 2020
1.2.3 Chemotherapy
1.2.4 Targeted Therapy
1.2.5 Immunotherapy (Biologic Therapy)
1.2.6 Hormonal Therapy
1.2.7 Others
1.3 Global Oncology Drugs Market by Application
1.3.1 Overview: Global Oncology Drugs Market Size by Application: 2020 Versus 2021 Versus 2026
1.3.2 Blood Cancer
1.3.3 Breast Cancer
1.3.4 Gastrointestinal Cancer
1.3.5 Prostate Cancer
1.3.6 Respiratory or Lung Cancer
1.3.7 Others
1.4 Global Oncology Drugs Market Size & Forecast
1.5 Global Oncology Drugs Market Size and Forecast by Region
1.5.1 Global Oncology Drugs Market Size by Region: 2016 VS 2021 VS 2026
1.5.2 Global Oncology Drugs Market Size by Region, (2016-2021)
1.5.3 North America Oncology Drugs Market Size and Prospect (2016-2026)
1.5.4 Europe Oncology Drugs Market Size and Prospect (2016-2026)
1.5.5 Asia-Pacific Oncology Drugs Market Size and Prospect (2016-2026)
1.5.6 South America Oncology Drugs Market Size and Prospect (2016-2026)
1.5.7 Middle East and Africa Oncology Drugs Market Size and Prospect (2016-2026)
1.6 Market Drivers, Restraints and Trends
1.6.1 Oncology Drugs Market Drivers
1.6.2 Oncology Drugs Market Restraints
1.6.3 Oncology Drugs Trends Analysis
2 Company Profiles
2.1 Roche
2.1.1 Roche Details
2.1.2 Roche Major Business
2.1.3 Roche Oncology Drugs Product and Solutions
2.1.4 Roche Oncology Drugs Revenue, Gross Margin and Market Share (2019-2021)
2.1.5 Roche Recent Developments and Future Plans
2.2 Celgene
2.2.1 Celgene Details
2.2.2 Celgene Major Business
2.2.3 Celgene Oncology Drugs Product and Solutions
2.2.4 Celgene Oncology Drugs Revenue, Gross Margin and Market Share (2019-2021)
2.2.5 Celgene Recent Developments and Future Plans
2.3 Novartis
2.3.1 Novartis Details
2.3.2 Novartis Major Business
2.3.3 Novartis Oncology Drugs Product and Solutions
2.3.4 Novartis Oncology Drugs Revenue, Gross Margin and Market Share (2019-2021)
2.3.5 Novartis Recent Developments and Future Plans
2.4 Bristol-Myers Squibb
2.4.1 Bristol-Myers Squibb Details
2.4.2 Bristol-Myers Squibb Major Business
2.4.3 Bristol-Myers Squibb Oncology Drugs Product and Solutions
2.4.4 Bristol-Myers Squibb Oncology Drugs Revenue, Gross Margin and Market Share (2019-2021)
2.4.5 Bristol-Myers Squibb Recent Developments and Future Plans
2.5 Johnson & Johnson
2.5.1 Johnson & Johnson Details
2.5.2 Johnson & Johnson Major Business
2.5.3 Johnson & Johnson Oncology Drugs Product and Solutions
2.5.4 Johnson & Johnson Oncology Drugs Revenue, Gross Margin and Market Share (2019-2021)
2.5.5 Johnson & Johnson Recent Developments and Future Plans
2.6 Merck & Co.
2.6.1 Merck & Co. Details
2.6.2 Merck & Co. Major Business
2.6.3 Merck & Co. Oncology Drugs Product and Solutions
2.6.4 Merck & Co. Oncology Drugs Revenue, Gross Margin and Market Share (2019-2021)
2.6.5 Merck & Co. Recent Developments and Future Plans
2.7 AstraZeneca
2.7.1 AstraZeneca Details
2.7.2 AstraZeneca Major Business
2.7.3 AstraZeneca Oncology Drugs Product and Solutions
2.7.4 AstraZeneca Oncology Drugs Revenue, Gross Margin and Market Share (2019-2021)
2.7.5 AstraZeneca Recent Developments and Future Plans
2.8 Pfizer
2.8.1 Pfizer Details
2.8.2 Pfizer Major Business
2.8.3 Pfizer Oncology Drugs Product and Solutions
2.8.4 Pfizer Oncology Drugs Revenue, Gross Margin and Market Share (2019-2021)
2.8.5 Pfizer Recent Developments and Future Plans
2.9 Amgen
2.9.1 Amgen Details
2.9.2 Amgen Major Business
2.9.3 Amgen Oncology Drugs Product and Solutions
2.9.4 Amgen Oncology Drugs Revenue, Gross Margin and Market Share (2019-2021)
2.9.5 Amgen Recent Developments and Future Plans
2.10 Eli Lilly
2.10.1 Eli Lilly Details
2.10.2 Eli Lilly Major Business
2.10.3 Eli Lilly Oncology Drugs Product and Solutions
2.10.4 Eli Lilly Oncology Drugs Revenue, Gross Margin and Market Share (2019-2021)
2.10.5 Eli Lilly Recent Developments and Future Plans
2.11 AbbVie
2.11.1 AbbVie Details
2.11.2 AbbVie Major Business
2.11.3 AbbVie Oncology Drugs Product and Solutions
2.11.4 AbbVie Oncology Drugs Revenue, Gross Margin and Market Share (2019-2021)
2.11.5 AbbVie Recent Developments and Future Plans
2.12 Takeda
2.12.1 Takeda Details
2.12.2 Takeda Major Business
2.12.3 Takeda Oncology Drugs Product and Solutions
2.12.4 Takeda Oncology Drugs Revenue, Gross Margin and Market Share (2019-2021)
2.12.5 Takeda Recent Developments and Future Plans
2.13 Astellas
2.13.1 Astellas Details
2.13.2 Astellas Major Business
2.13.3 Astellas Oncology Drugs Product and Solutions
2.13.4 Astellas Oncology Drugs Revenue, Gross Margin and Market Share (2019-2021)
2.13.5 Astellas Recent Developments and Future Plans
2.14 Ipsen
2.14.1 Ipsen Details
2.14.2 Ipsen Major Business
2.14.3 Ipsen Oncology Drugs Product and Solutions
2.14.4 Ipsen Oncology Drugs Revenue, Gross Margin and Market Share (2019-2021)
2.14.5 Ipsen Recent Developments and Future Plans
2.15 Sanofi
2.15.1 Sanofi Details
2.15.2 Sanofi Major Business
2.15.3 Sanofi Oncology Drugs Product and Solutions
2.15.4 Sanofi Oncology Drugs Revenue, Gross Margin and Market Share (2019-2021)
2.15.5 Sanofi Recent Developments and Future Plans
2.16 Bayer
2.16.1 Bayer Details
2.16.2 Bayer Major Business
2.16.3 Bayer Oncology Drugs Product and Solutions
2.16.4 Bayer Oncology Drugs Revenue, Gross Margin and Market Share (2019-2021)
2.16.5 Bayer Recent Developments and Future Plans
2.17 Biogen Idec
2.17.1 Biogen Idec Details
2.17.2 Biogen Idec Major Business
2.17.3 Biogen Idec Oncology Drugs Product and Solutions
2.17.4 Biogen Idec Oncology Drugs Revenue, Gross Margin and Market Share (2019-2021)
2.17.5 Biogen Idec Recent Developments and Future Plans
2.18 Teva
2.18.1 Teva Details
2.18.2 Teva Major Business
2.18.3 Teva Oncology Drugs Product and Solutions
2.18.4 Teva Oncology Drugs Revenue, Gross Margin and Market Share (2019-2021)
2.18.5 Teva Recent Developments and Future Plans
2.19 Otsuka
2.19.1 Otsuka Details
2.19.2 Otsuka Major Business
2.19.3 Otsuka Oncology Drugs Product and Solutions
2.19.4 Otsuka Oncology Drugs Revenue, Gross Margin and Market Share (2019-2021)
2.19.5 Otsuka Recent Developments and Future Plans
2.20 Eisai
2.20.1 Eisai Details
2.20.2 Eisai Major Business
2.20.3 Eisai Oncology Drugs Product and Solutions
2.20.4 Eisai Oncology Drugs Revenue, Gross Margin and Market Share (2019-2021)
2.20.5 Eisai Recent Developments and Future Plans
2.21 Merck KGaA
2.21.1 Merck KGaA Details
2.21.2 Merck KGaA Major Business
2.21.3 Merck KGaA Oncology Drugs Product and Solutions
2.21.4 Merck KGaA Oncology Drugs Revenue, Gross Margin and Market Share (2019-2021)
2.21.5 Merck KGaA Recent Developments and Future Plans
2.22 Gilead Sciences
2.22.1 Gilead Sciences Details
2.22.2 Gilead Sciences Major Business
2.22.3 Gilead Sciences Oncology Drugs Product and Solutions
2.22.4 Gilead Sciences Oncology Drugs Revenue, Gross Margin and Market Share (2019-2021)
2.22.5 Gilead Sciences Recent Developments and Future Plans
3 Market Competition, by Players
3.1 Global Oncology Drugs Revenue and Share by Players (2019-2021)
3.2 Market Concentration Rate
3.2.1 Top 3 Oncology Drugs Players Market Share
3.2.2 Top 10 Oncology Drugs Players Market Share
3.2.3 Market Competition Trend
3.3 Oncology Drugs Players Head Office, Products and Services Provided
3.4 Mergers & Acquisitions
3.5 New Entrants and Expansion Plans
4 Market Size Segment by Type
4.1 Global Oncology Drugs Revenue and Market Share by Type (2016-2021)
4.2 Global Oncology Drugs Market Forecast by Type (2021-2026)
5 Market Size Segment by Application
5.1 Global Oncology Drugs Revenue Market Share by Application (2016-2021)
5.2 Oncology Drugs Market Forecast by Application (2021-2026)
6 North America by Country, by Type, and by Application
6.1 North America Oncology Drugs Revenue by Type (2016-2026)
6.2 North America Oncology Drugs Revenue by Application (2016-2026)
6.3 North America Oncology Drugs Market Size by Country
6.3.1 North America Oncology Drugs Revenue by Country (2016-2026)
6.3.2 United States Oncology Drugs Market Size and Forecast (2016-2026)
6.3.3 Canada Oncology Drugs Market Size and Forecast (2016-2026)
6.3.4 Mexico Oncology Drugs Market Size and Forecast (2016-2026)
7 Europe by Country, by Type, and by Application
7.1 Europe Oncology Drugs Revenue by Type (2016-2026)
7.2 Europe Oncology Drugs Revenue by Application (2016-2026)
7.3 Europe Oncology Drugs Market Size by Country
7.3.1 Europe Oncology Drugs Revenue by Country (2016-2026)
7.3.2 Germany Oncology Drugs Market Size and Forecast (2016-2026)
7.3.3 France Oncology Drugs Market Size and Forecast (2016-2026)
7.3.4 United Kingdom Oncology Drugs Market Size and Forecast (2016-2026)
7.3.5 Russia Oncology Drugs Market Size and Forecast (2016-2026)
7.3.6 Italy Oncology Drugs Market Size and Forecast (2016-2026)
8 Asia-Pacific by Region, by Type, and by Application
8.1 Asia-Pacific Oncology Drugs Revenue by Type (2016-2026)
8.2 Asia-Pacific Oncology Drugs Revenue by Application (2016-2026)
8.3 Asia-Pacific Oncology Drugs Market Size by Region
8.3.1 Asia-Pacific Oncology Drugs Revenue by Region (2016-2026)
8.3.2 China Oncology Drugs Market Size and Forecast (2016-2026)
8.3.3 Japan Oncology Drugs Market Size and Forecast (2016-2026)
8.3.4 South Korea Oncology Drugs Market Size and Forecast (2016-2026)
8.3.5 India Oncology Drugs Market Size and Forecast (2016-2026)
8.3.6 Southeast Asia Oncology Drugs Market Size and Forecast (2016-2026)
8.3.7 Australia Oncology Drugs Market Size and Forecast (2016-2026)
9 South America by Country, by Type, and by Application
9.1 South America Oncology Drugs Revenue by Type (2016-2026)
9.2 South America Oncology Drugs Revenue by Application (2016-2026)
9.3 South America Oncology Drugs Market Size by Country
9.3.1 South America Oncology Drugs Revenue by Country (2016-2026)
9.3.2 Brazil Oncology Drugs Market Size and Forecast (2016-2026)
9.3.3 Argentina Oncology Drugs Market Size and Forecast (2016-2026)
10 Middle East & Africa by Country, by Type, and by Application
10.1 Middle East & Africa Oncology Drugs Revenue by Type (2016-2026)
10.2 Middle East & Africa Oncology Drugs Revenue by Application (2016-2026)
10.3 Middle East & Africa Oncology Drugs Market Size by Country
10.3.1 Middle East & Africa Oncology Drugs Revenue by Country (2016-2026)
10.3.2 Turkey Oncology Drugs Market Size and Forecast (2016-2026)
10.3.3 Saudi Arabia Oncology Drugs Market Size and Forecast (2016-2026)
10.3.4 UAE Oncology Drugs Market Size and Forecast (2016-2026)
11 Research Findings and Conclusion
12 Appendix
12.1 Methodology
12.2 Research Process and Data Source
12.3 Disclaimer

List of Tables
Table 1. Global Oncology Drugs Revenue by Type, (USD Million), 2020 VS 2021 VS 2026
Table 2. Global Oncology Drugs Revenue by Application, (USD Million), 2020 VS 2021 VS 2026
Table 3. Global Market Oncology Drugs Revenue (Million USD) Comparison by Region (2016 VS 2021 VS 2026)
Table 4. Global Oncology Drugs Revenue (USD Million) by Region (2016-2021)
Table 5. Global Oncology Drugs Revenue Market Share by Region (2021-2026)
Table 6. Roche Corporate Information, Head Office, and Major Competitors
Table 7. Roche Major Business
Table 8. Roche Oncology Drugs Product and Solutions
Table 9. Roche Oncology Drugs Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 10. Celgene Corporate Information, Head Office, and Major Competitors
Table 11. Celgene Major Business
Table 12. Celgene Oncology Drugs Product and Solutions
Table 13. Celgene Oncology Drugs Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 14. Novartis Corporate Information, Head Office, and Major Competitors
Table 15. Novartis Major Business
Table 16. Novartis Oncology Drugs Product and Solutions
Table 17. Novartis Oncology Drugs Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 18. Bristol-Myers Squibb Corporate Information, Head Office, and Major Competitors
Table 19. Bristol-Myers Squibb Major Business
Table 20. Bristol-Myers Squibb Oncology Drugs Product and Solutions
Table 21. Bristol-Myers Squibb Oncology Drugs Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 22. Johnson & Johnson Corporate Information, Head Office, and Major Competitors
Table 23. Johnson & Johnson Major Business
Table 24. Johnson & Johnson Oncology Drugs Product and Solutions
Table 25. Johnson & Johnson Oncology Drugs Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 26. Merck & Co. Corporate Information, Head Office, and Major Competitors
Table 27. Merck & Co. Major Business
Table 28. Merck & Co. Oncology Drugs Product and Solutions
Table 29. Merck & Co. Oncology Drugs Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 30. AstraZeneca Corporate Information, Head Office, and Major Competitors
Table 31. AstraZeneca Major Business
Table 32. AstraZeneca Oncology Drugs Product and Solutions
Table 33. AstraZeneca Oncology Drugs Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 34. Pfizer Corporate Information, Head Office, and Major Competitors
Table 35. Pfizer Major Business
Table 36. Pfizer Oncology Drugs Product and Solutions
Table 37. Pfizer Oncology Drugs Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 38. Amgen Corporate Information, Head Office, and Major Competitors
Table 39. Amgen Major Business
Table 40. Amgen Oncology Drugs Product and Solutions
Table 41. Amgen Oncology Drugs Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 42. Eli Lilly Corporate Information, Head Office, and Major Competitors
Table 43. Eli Lilly Major Business
Table 44. Eli Lilly Oncology Drugs Product and Solutions
Table 45. Eli Lilly Oncology Drugs Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 46. AbbVie Corporate Information, Head Office, and Major Competitors
Table 47. AbbVie Major Business
Table 48. AbbVie Oncology Drugs Product and Solutions
Table 49. AbbVie Oncology Drugs Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 50. Takeda Corporate Information, Head Office, and Major Competitors
Table 51. Takeda Major Business
Table 52. Takeda Oncology Drugs Product and Solutions
Table 53. Takeda Oncology Drugs Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 54. Astellas Corporate Information, Head Office, and Major Competitors
Table 55. Astellas Major Business
Table 56. Astellas Oncology Drugs Product and Solutions
Table 57. Astellas Oncology Drugs Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 58. Ipsen Corporate Information, Head Office, and Major Competitors
Table 59. Ipsen Major Business
Table 60. Ipsen Oncology Drugs Product and Solutions
Table 61. Ipsen Oncology Drugs Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 62. Sanofi Corporate Information, Head Office, and Major Competitors
Table 63. Sanofi Major Business
Table 64. Sanofi Oncology Drugs Product and Solutions
Table 65. Sanofi Oncology Drugs Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 66. Bayer Corporate Information, Head Office, and Major Competitors
Table 67. Bayer Major Business
Table 68. Bayer Oncology Drugs Product and Solutions
Table 69. Bayer Oncology Drugs Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 70. Biogen Idec Corporate Information, Head Office, and Major Competitors
Table 71. Biogen Idec Major Business
Table 72. Biogen Idec Oncology Drugs Product and Solutions
Table 73. Biogen Idec Oncology Drugs Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 74. Teva Corporate Information, Head Office, and Major Competitors
Table 75. Teva Major Business
Table 76. Teva Oncology Drugs Product and Solutions
Table 77. Teva Oncology Drugs Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 78. Otsuka Corporate Information, Head Office, and Major Competitors
Table 79. Otsuka Major Business
Table 80. Otsuka Oncology Drugs Product and Solutions
Table 81. Otsuka Oncology Drugs Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 82. Eisai Corporate Information, Head Office, and Major Competitors
Table 83. Eisai Major Business
Table 84. Eisai Oncology Drugs Product and Solutions
Table 85. Eisai Oncology Drugs Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 86. Merck KGaA Corporate Information, Head Office, and Major Competitors
Table 87. Merck KGaA Major Business
Table 88. Merck KGaA Oncology Drugs Product and Solutions
Table 89. Merck KGaA Oncology Drugs Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 90. Gilead Sciences Corporate Information, Head Office, and Major Competitors
Table 91. Gilead Sciences Major Business
Table 92. Gilead Sciences Oncology Drugs Product and Solutions
Table 93. Gilead Sciences Oncology Drugs Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 94. Global Oncology Drugs Revenue (USD Million) by Players (2019-2021)
Table 95. Global Oncology Drugs Revenue Share by Players (2019-2021)
Table 96. Breakdown of Oncology Drugs by Company Type (Tier 1, Tier 2 and Tier 3)
Table 97. Oncology Drugs Players Head Office, Products and Services Provided
Table 98. Oncology Drugs Mergers & Acquisitions in the Past Five Years
Table 99. Oncology Drugs New Entrants and Expansion Plans
Table 100. Global Oncology Drugs Revenue (USD Million) by Type (2016-2021)
Table 101. Global Oncology Drugs Revenue Share by Type (2016-2021)
Table 102. Global Oncology Drugs Revenue Forecast by Type (2021-2026)
Table 103. Global Oncology Drugs Revenue by Application (2016-2021)
Table 104. Global Oncology Drugs Revenue Forecast by Application (2021-2026)
Table 105. North America Oncology Drugs Revenue by Type (2016-2021) & (USD Million)
Table 106. North America Oncology Drugs Revenue by Type (2021-2026) & (USD Million)
Table 107. North America Oncology Drugs Revenue by Application (2016-2021) & (USD Million)
Table 108. North America Oncology Drugs Revenue by Application (2021-2026) & (USD Million)
Table 109. North America Oncology Drugs Revenue by Country (2016-2021) & (USD Million)
Table 110. North America Oncology Drugs Revenue by Country (2021-2026) & (USD Million)
Table 111. Europe Oncology Drugs Revenue by Type (2016-2021) & (USD Million)
Table 112. Europe Oncology Drugs Revenue by Type (2021-2026) & (USD Million)
Table 113. Europe Oncology Drugs Revenue by Application (2016-2021) & (USD Million)
Table 114. Europe Oncology Drugs Revenue by Application (2021-2026) & (USD Million)
Table 115. Europe Oncology Drugs Revenue by Country (2016-2021) & (USD Million)
Table 116. Europe Oncology Drugs Revenue by Country (2021-2026) & (USD Million)
Table 117. Asia-Pacific Oncology Drugs Revenue by Type (2016-2021) & (USD Million)
Table 118. Asia-Pacific Oncology Drugs Revenue by Type (2021-2026) & (USD Million)
Table 119. Asia-Pacific Oncology Drugs Revenue by Application (2016-2021) & (USD Million)
Table 120. Asia-Pacific Oncology Drugs Revenue by Application (2021-2026) & (USD Million)
Table 121. Asia-Pacific Oncology Drugs Revenue by Region (2016-2021) & (USD Million)
Table 122. Asia-Pacific Oncology Drugs Revenue by Region (2021-2026) & (USD Million)
Table 123. South America Oncology Drugs Revenue by Type (2016-2021) & (USD Million)
Table 124. South America Oncology Drugs Revenue by Type (2021-2026) & (USD Million)
Table 125. South America Oncology Drugs Revenue by Application (2016-2021) & (USD Million)
Table 126. South America Oncology Drugs Revenue by Application (2021-2026) & (USD Million)
Table 127. South America Oncology Drugs Revenue by Country (2016-2021) & (USD Million)
Table 128. South America Oncology Drugs Revenue by Country (2021-2026) & (USD Million)
Table 129. Middle East & Africa Oncology Drugs Revenue by Type (2016-2021) & (USD Million)
Table 130. Middle East & Africa Oncology Drugs Revenue by Type (2021-2026) & (USD Million)
Table 131. Middle East & Africa Oncology Drugs Revenue by Application (2016-2021) & (USD Million)
Table 132. Middle East & Africa Oncology Drugs Revenue by Application (2021-2026) & (USD Million)
Table 133. Middle East & Africa Oncology Drugs Revenue by Country (2016-2021) & (USD Million)
Table 134. Middle East & Africa Oncology Drugs Revenue by Country (2021-2026) & (USD Million)
List of Figures
Figure 1. Oncology Drugs Picture
Figure 2. Global Oncology Drugs Revenue Market Share by Type in 2020
Figure 3. Chemotherapy
Figure 4. Targeted Therapy
Figure 5. Immunotherapy (Biologic Therapy)
Figure 6. Hormonal Therapy
Figure 7. Others
Figure 8. Oncology Drugs Revenue Market Share by Application in 2020
Figure 9. Blood Cancer Picture
Figure 10. Breast Cancer Picture
Figure 11. Gastrointestinal Cancer Picture
Figure 12. Prostate Cancer Picture
Figure 13. Respiratory or Lung Cancer Picture
Figure 14. Others Picture
Figure 15. Global Oncology Drugs Revenue, (USD Million): 2020 VS 2021 VS 2026
Figure 16. Global Oncology Drugs Revenue and Forecast (2016-2026) & (USD Million)
Figure 17. Global Oncology Drugs Revenue Market Share by Region (2016-2026)
Figure 18. Global Oncology Drugs Revenue Market Share by Region in 2020
Figure 19. North America Oncology Drugs Revenue (USD Million) and Growth Rate (2016-2026)
Figure 20. Europe Oncology Drugs Revenue (USD Million) and Growth Rate (2016-2026)
Figure 21. Asia-Pacific Oncology Drugs Revenue (USD Million) and Growth Rate (2016-2026)
Figure 22. South America Oncology Drugs Revenue (USD Million) and Growth Rate (2016-2026)
Figure 23. Middle East and Africa Oncology Drugs Revenue (USD Million) and Growth Rate (2016-2026)
Figure 24. Oncology Drugs Market Drivers
Figure 25. Oncology Drugs Market Restraints
Figure 26. Oncology Drugs Market Trends
Figure 27. Roche Recent Developments and Future Plans
Figure 28. Celgene Recent Developments and Future Plans
Figure 29. Novartis Recent Developments and Future Plans
Figure 30. Bristol-Myers Squibb Recent Developments and Future Plans
Figure 31. Johnson & Johnson Recent Developments and Future Plans
Figure 32. Merck & Co. Recent Developments and Future Plans
Figure 33. AstraZeneca Recent Developments and Future Plans
Figure 34. Pfizer Recent Developments and Future Plans
Figure 35. Amgen Recent Developments and Future Plans
Figure 36. Eli Lilly Recent Developments and Future Plans
Figure 37. AbbVie Recent Developments and Future Plans
Figure 38. Takeda Recent Developments and Future Plans
Figure 39. Astellas Recent Developments and Future Plans
Figure 40. Ipsen Recent Developments and Future Plans
Figure 41. Sanofi Recent Developments and Future Plans
Figure 42. Bayer Recent Developments and Future Plans
Figure 43. Biogen Idec Recent Developments and Future Plans
Figure 44. Teva Recent Developments and Future Plans
Figure 45. Otsuka Recent Developments and Future Plans
Figure 46. Eisai Recent Developments and Future Plans
Figure 47. Merck KGaA Recent Developments and Future Plans
Figure 48. Gilead Sciences Recent Developments and Future Plans
Figure 49. Global Oncology Drugs Revenue Share by Players in 2020
Figure 50. Oncology Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
Figure 51. Global Top 3 Players Oncology Drugs Revenue Market Share in 2020
Figure 52. Global Top 10 Players Oncology Drugs Revenue Market Share in 2020
Figure 53. Key Players Market Share Trend (Top 3 Market Share: 2019 VS 2020 VS 2021)
Figure 54. Global Oncology Drugs Revenue Share by Type in 2020
Figure 55. Global Oncology Drugs Market Share Forecast by Type (2021-2026)
Figure 56. Global Oncology Drugs Revenue Share by Application in 2020
Figure 57. Global Oncology Drugs Market Share Forecast by Application (2021-2026)
Figure 58. North America Oncology Drugs Sales Market Share by Type (2016-2026)
Figure 59. North America Oncology Drugs Sales Market Share by Application (2016-2026)
Figure 60. North America Oncology Drugs Revenue Market Share by Country (2016-2026)
Figure 61. United States Oncology Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 62. Canada Oncology Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 63. Mexico Oncology Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 64. Europe Oncology Drugs Sales Market Share by Type (2016-2026)
Figure 65. Europe Oncology Drugs Sales Market Share by Application (2016-2026)
Figure 66. Europe Oncology Drugs Revenue Market Share by Country (2016-2026)
Figure 67. Germany Oncology Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 68. France Oncology Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 69. United Kingdom Oncology Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 70. Russia Oncology Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 71. Italy Oncology Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 72. Asia-Pacific Oncology Drugs Sales Market Share by Type (2016-2026)
Figure 73. Asia-Pacific Oncology Drugs Sales Market Share by Application (2016-2026)
Figure 74. Asia-Pacific Oncology Drugs Revenue Market Share by Region (2016-2026)
Figure 75. China Oncology Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 76. Japan Oncology Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 77. South Korea Oncology Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 78. India Oncology Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 79. Southeast Asia Oncology Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 80. Australia Oncology Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 81. South America Oncology Drugs Sales Market Share by Type (2016-2026)
Figure 82. South America Oncology Drugs Sales Market Share by Application (2016-2026)
Figure 83. South America Oncology Drugs Revenue Market Share by Country (2016-2026)
Figure 84. Brazil Oncology Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 85. Argentina Oncology Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 86. Middle East and Africa Oncology Drugs Sales Market Share by Type (2016-2026)
Figure 87. Middle East and Africa Oncology Drugs Sales Market Share by Application (2016-2026)
Figure 88. Middle East and Africa Oncology Drugs Revenue Market Share by Country (2016-2026)
Figure 89. Turkey Oncology Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 90. Saudi Arabia Oncology Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 91. UAE Oncology Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 92. Methodology
Figure 93. Research Process and Data Source
  • Global 5-Fluorouracil Market Research Report 2024
    Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 76
    The global 5-Fluorouracil market was valued at US$ 283 million in 2023 and is anticipated to reach US$ 487.9 million by 2030, witnessing a CAGR of 4.3% during The forecast period 2024-2030. North American market for 5-Fluorouracil is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for 5-Fluorouracil is estimated to increase from $ million in 2023 to reach $ million by ......
  • Global Carboplatin Market Research Report 2024
    Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 79
    The global Carboplatin market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during The forecast period 2024-2030. North American market for Carboplatin is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for Carboplatin is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % d......
  • Global Neutropenia Drugs Market Research Report 2024
    Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 96
    The global Neutropenia Drugs market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during The forecast period 2024-2030. The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during The next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, The chemical drug market is estimated to increa......
  • Global Small Molecule Cancer Drug Market Research Report 2024
    Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 85
    The global Small Molecule Cancer Drug market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during The forecast period 2024-2030. The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during The next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, The chemical drug market is estimated ......
  • Global Capecitabine Market Research Report 2024
    Published: 08-Jan-2024        Price: US 2900 Onwards        Pages: 80
    Capecitabine is an orally-administered chemotherapeutic agent used in The treatment of metastatic breast and colorectal cancers. Capecitabine is a prodrug, which is enzymatically converted to fluorouracil (antimetabolite) in The tumor, where it inhibits DNA synthesis and slows growth of tumor tissue. Common side effects include abdominal pain, vomiting, diarrhea, weakness, and rashes. Other severe side effects include blood clotting problems, allergic reactions, heart problems, and low blo......
  • Global Oxaliplatin Market Research Report 2024
    Published: 08-Jan-2024        Price: US 2900 Onwards        Pages: 104
    Oxaliplatin is a platinum-based anticancer drug with colorless or nearly colorless transparent liquid. It is often used for metastatic colorectal cancer treatment or adjuvant therapy The third stage colon cancer after resecting primary tumor completely. In this report, only The finished drug is covered, exclude API. The global Oxaliplatin market was valued at US$ 897.5 million in 2023 and is anticipated to reach US$ 1641.5 million by 2030, witnessing a CAGR of 8.9% duri......
  • Global Cancer Treatment Drugs Market Growth 2024-2030
    Published: 04-Jan-2024        Price: US 3660 Onwards        Pages: 158
    According to our LPI (LP Information) latest study, the global Cancer Treatment Drugs market size was valued at US$ 174990 million in 2023. With growing demand in downstream market, the Cancer Treatment Drugs is forecast to a readjusted size of US$ 322540 million by 2030 with a CAGR of 9.1% during review period. The research report highlights the growth potential of the global Cancer Treatment Drugs market. Cancer Treatment Drugs are expected to show stable growth in the future market. H......
  • Global Capecitabine Market Growth 2024-2030
    Published: 04-Jan-2024        Price: US 3660 Onwards        Pages: 93
    According to our LPI (LP Information) latest study, the global Capecitabine market size was valued at US$ 1003.9 million in 2023. With growing demand in downstream market, the Capecitabine is forecast to a readjusted size of US$ 975.1 million by 2030 with a CAGR of -0.4% during review period. The research report highlights the growth potential of the global Capecitabine market. Capecitabine are expected to show stable growth in the future market. However, product differentiation, reducin......
  • Global Methotrexate Market Growth 2024-2030
    Published: 04-Jan-2024        Price: US 3660 Onwards        Pages: 95
    According to our LPI (LP Information) latest study, the global Methotrexate market size was valued at US$ 506 million in 2023. With growing demand in downstream market, the Methotrexate is forecast to a readjusted size of US$ 613.9 million by 2030 with a CAGR of 2.8% during review period. The research report highlights the growth potential of the global Methotrexate market. Methotrexate are expected to show stable growth in the future market. However, product differentiation, reducing co......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - [email protected] / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs